Skip to main content

2021

Press release

Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction

Pharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel, Switzerland.

Read more
Press release

Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM

Pharming Group N.V. announces the publication of its Annual Report for the year ended 31 December 2020. In addition, the Company’s 2021 Annual General Meeting (AGM) will be held at 16:00CET on Wednesday, 19 May 2021. The Notice to Convene, Explanatory Notes, meeting documents and Form of Proxy can be found on the Company’s website, under Investors/Shareholders’ Meetings.

Read more

2020

Filter

Cookies: This website uses cookies Check the cookies page for more information Accept Decline